2021, Vol. 3, Issue 2, Part A

Author(s): Dr. Kavangal Dhananjay and Dr. Mamatha Pulloori

Abstract: Nonalcoholic fatty liver disease (NAFLD) is emerging as an important cause of chronic liver disease in worldwide. Liver biopsy is a gold standard procedure in the diagnosis and staging of NAFLD, but there are several non-invasive diagnostic procedures have been emerged for the early diagnosis of liver fibrosis. The present study was designed to assess the efficacy of APRI to fibroscan as a marker for early fibrosis in cases with non-alcoholic fatty liver diseases. A total of 120 cases, which are newly diagnosed with non-alcoholic fatty liver disease attending OPD were recruited. Laboratory investigation results were obtained after overnight for evaluation of complete blood count, blood glucose levels, albumin, total bilirubin, platelet count, prothrombin time international normalized ratio, cholesterol, triglyceride (TG), serum urea, creatinine, HBsAg, HCV. Radiological evaluation was conducted by USG abdomen and fibroscan. The value of triglyceride was below 150mg/dl in 34.16% cases, between 150-200mg/dl in 45.83% cases and >200mg/dl in 20% cases. The fasting blood sugar was >100 in 40% cases and <100 in 60% cases. The aspartate aminotransferase levels was <30IU/L in 17.5% cases, 31-40 IU/L in 29.16%, 41-50 IU/L in 33.33%, and >50 IU/L in 20% cases. The platelets count was <100 in 29.16% cases, 101-150 in 53.33% cases, 151-200 in 12.5% cases and >200 in 5% cases. The fibroscan values was <7.0 in 45% cases, 7.1-8.9 in 35% cases and >9.0 in 20% cases. The APRI score was <0.7 in 33.3% cases, 0.7-1.0 in 26.66% cases and >1.0 in 40% cases. There is a significant correlation between fibroscan and APRI in cases with NAFLD. Fibroscan and APRI are uniformly efficient in predicting liver fibrosis. The use of APRI >0.7 would avoid the need for fibroscan.

DOI: 10.22271/27069567.2021.v3.i2a.215

Pages: 37-40 | Views: 670 | Downloads: 202

Download Full Article: Click Here